MCID: CRV002
MIFTS: 47

Cervix Uteri Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 12 15
Carcinoma in Situ of Uterine Cervix 12 73
Cervical Intraepithelial Neoplasia 44 73
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 12
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 73
Squamous Intraepithelial Neoplasia, Grade Iii 12
Cin Iii - Carcinoma in Situ of Cervix 12
Severe Dysplasia of the Cervix Uteri 12
Cin Iii - Severe Dyskaryosis 12
Carcinoma in Situ of Cervix 12
Carcinoma of Cervix Stage 0 12
Severe Dysplasia of Cervix 12
Cervix Ca in Situ 12
Cin Iii 12

Classifications:



Summaries for Cervix Uteri Carcinoma in Situ

MalaCards based summary : Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to cervicitis and cervical intraepithelial neoplasia. An important gene associated with Cervix Uteri Carcinoma in Situ is SERPIND1 (Serpin Family D Member 1), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Oncogene Induced Senescence. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and breast, and related phenotype is mortality/aging.

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Related Disease Score Top Affiliating Genes
1 cervicitis 31.0 CDKN2A SERPIND1
2 cervical intraepithelial neoplasia 29.9 CDKN2A FHIT KRT17
3 chronic cervicitis 10.7 GP6 SERPIND1
4 balanoposthitis 10.7 CDKN2A GP6
5 brain stem astrocytic neoplasm 10.6 CDKN2A TP53
6 keratinizing squamous cell carcinoma 10.6 CDKN2A TP53
7 spitz nevus 10.6 CDKN2A TP53
8 bladder carcinoma in situ 10.6 CDKN2A TP53
9 bartholin's gland benign neoplasm 10.6 CDKN2A TP53
10 vulva squamous cell carcinoma 10.6 CDKN2A TP53
11 thyroid lymphoma 10.6 CDKN2A TP53
12 nasal cavity adenocarcinoma 10.6 CDKN2A TP53
13 bone squamous cell carcinoma 10.6 CDKN2A TP53
14 scrotal carcinoma 10.6 CDKN2A TP53
15 anal squamous cell carcinoma 10.5 CDKN2A TP53
16 glycogen-rich clear cell breast carcinoma 10.5 CDKN2A TP53
17 gastric adenosquamous carcinoma 10.5 CDKN2A TP53
18 oral leukoplakia 10.5 CDKN2A TP53
19 schneiderian carcinoma 10.5 CDKN2A TP53
20 meningeal melanomatosis 10.5 CDKN2A TP53
21 dedifferentiated liposarcoma 10.5 CDKN2A TP53
22 endocervical adenocarcinoma 10.5 CDKN2A TP53
23 cervix small cell carcinoma 10.5 CDKN2A TP53
24 cervical adenosarcoma 10.5 GP5 GP6
25 necrotizing sialometaplasia 10.5 CDKN2A TP53
26 biliary tract neoplasm 10.4 CDKN2A TP53
27 cervix disease 10.4 CDKN2A GP6 SERPIND1
28 inverted papilloma 10.4 CDKN2A TP53
29 optic nerve neoplasm 10.4 CDKN2A TP53
30 recessive dystrophic epidermolysis bullosa 10.4 CDKN2A TP53
31 vulva cancer 10.4 CDKN2A TP53
32 squamous cell papilloma 10.4 CDKN2A TP53
33 cervical clear cell adenocarcinoma 10.4 CDKN2A GP5
34 juvenile pilocytic astrocytoma 10.3 CDKN2A TP53
35 anogenital venereal wart 10.3 CDKN2A GP6 TP53
36 oropharynx cancer 10.3 CDKN2A GP6 TP53
37 basaloid squamous cell carcinoma 10.2 CDKN2A KRT17 TP53
38 gastrointestinal system benign neoplasm 10.2 CDKN2A TP53
39 actinic keratosis 10.2 CDKN2A KRT17 TP53
40 skin squamous cell carcinoma 10.2 CDKN2A TP53
41 early invasive cervical adenocarcinoma 10.1 CDKN2A INSM1
42 fallopian tube endometrioid adenocarcinoma 10.1 CDKN2A INSM1
43 inverted follicular keratosis 10.1 GP5 GP6 KRT17
44 keratocystic odontogenic tumor 10.1 FHIT TP53
45 megaesophagus 10.0 CDKN2A FHIT TP53
46 suppressor of tumorigenicity 3 10.0 CDKN2A FHIT TP53
47 barrett's adenocarcinoma 10.0 CDKN2A FHIT TP53
48 cervix carcinoma 10.0 CDKN2A FHIT TP53
49 malignant mesenchymoma 10.0 FHIT TP53
50 cervical carcinosarcoma 10.0 GP5 GP6 TP53

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):


Endometriosis of Uterus Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:



Diseases related to Cervix Uteri Carcinoma in Situ

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

MGI Mouse Phenotypes related to Cervix Uteri Carcinoma in Situ:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.28 CDKN2A CINP COL27A1 FHIT GP6 INSM1

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
2
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
4
Tamoxifen Approved Phase 3 10540-29-1 2733526
5
Imiquimod Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 99011-02-6 57469
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
7
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
8
Menthol Approved Phase 3,Not Applicable 2216-51-5 16666
9
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
10
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
11
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
12
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
13
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
14
Heparin Approved, Investigational Phase 2, Phase 3 9005-49-6 772 46507594
15
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
16
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 43805 6857599
17
Floxuridine Approved Phase 2, Phase 3 50-91-9 5790
18
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
19
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
21
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
22
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
23
leucovorin Approved, Nutraceutical Phase 2, Phase 3 58-05-9 143 6006
24
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
25
Doxil Approved June 1999 Phase 3,Phase 2 31703
26 Peripheral Nervous System Agents Phase 2, Phase 3,Early Phase 1
27 Anti-Inflammatory Agents Phase 2, Phase 3,Early Phase 1
28 Antirheumatic Agents Phase 3,Phase 2,Early Phase 1
29 interferons Phase 2, Phase 3,Phase 1,Not Applicable
30 Alkylating Agents Phase 3,Phase 2
31 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1,Not Applicable
32 Selective Estrogen Receptor Modulators Phase 3
33 Mitogens Phase 3,Phase 2
34 Albumin-Bound Paclitaxel Phase 3,Phase 2
35 Steroid Synthesis Inhibitors Phase 3,Phase 2
36 Topoisomerase Inhibitors Phase 3,Phase 2
37 Hormone Antagonists Phase 3,Phase 2
38 Hormones Phase 3,Phase 2
39 Vaccines Phase 3,Phase 1,Phase 2,Not Applicable
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
41 Anti-Bacterial Agents Phase 3,Phase 2
42 Antibiotics, Antitubercular Phase 3,Phase 2
43 Estrogen Antagonists Phase 3,Phase 2
44 Estrogen Receptor Modulators Phase 3
45 Estrogens Phase 3,Phase 2
46 Antibodies Phase 3,Phase 1
47 Immunoglobulins Phase 3,Phase 1
48 Immunosuppressive Agents Phase 3,Phase 2
49 Interferon Inducers Phase 2, Phase 3,Phase 1,Not Applicable
50 Protein Kinase Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
2 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
3 Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
4 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
5 Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Completed NCT00237562 Phase 3
6 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
7 Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study Completed NCT00929526 Phase 3
8 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
9 Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer Completed NCT00045032 Phase 3 Herceptin;Herceptin
10 Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects Completed NCT00937950 Phase 3
11 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
12 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
13 REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) Recruiting NCT03185013 Phase 3
14 EPA for Metastasis Trial 2 Recruiting NCT03428477 Phase 3 Icosapent Ethyl
15 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
16 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer Active, not recruiting NCT01608451 Phase 3 Cholecalciferol;Inj. Progesterone
17 Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer Not yet recruiting NCT02529774 Phase 2, Phase 3 Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6);Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
18 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
19 Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3) Completed NCT02195089 Phase 1, Phase 2 BLS_ILS_E710c 500mg;BLS_ILB_710c 1000mg;BLS_ILS_E710c 1500mg
20 Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia Completed NCT02139267 Phase 2
21 A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 Completed NCT01304524 Phase 2
22 Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Completed NCT00054041 Phase 2
23 SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia Completed NCT00075569 Phase 2
24 Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia Completed NCT00081263 Phase 2 Celecoxib
25 A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection Completed NCT01022346 Phase 2 Placebo;RO5217790
26 A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions. Completed NCT02976987 Phase 2 Cidofovir
27 Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005) Completed NCT00365378 Phase 2
28 Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery Completed NCT00436566 Phase 2 cyclophosphamide;doxorubicin hydrochloride;lapatinib ditosylate;paclitaxel
29 Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine Completed NCT00316693 Phase 2
30 A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer. Completed NCT00717405 Phase 2 Standard chemotherapy;bevacizumab [Avastin];trastuzumab [Herceptin]
31 A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia Recruiting NCT01925378 Phase 2 Nelfinavir
32 IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 Recruiting NCT03267680 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
33 Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions Recruiting NCT03233412 Phase 2 Imiquimod
34 PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Recruiting NCT01723774 Phase 2 PD0332991;Anastrozole;Goserelin
35 Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) Active, not recruiting NCT02596243 Phase 2
36 S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix Withdrawn NCT00072540 Phase 2 celecoxib
37 Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 Completed NCT01634503 Phase 1
38 Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia Recruiting NCT00788164 Phase 1 imiquimod
39 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1 EF5
40 Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) Unknown status NCT02554344 Early Phase 1 Curcumin
41 Follow-up of Abnormal and Inadequate Smear-test Results Unknown status NCT02002468 Not Applicable
42 Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer Unknown status NCT01371695
43 Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia Unknown status NCT02406352 Not Applicable
44 HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN Unknown status NCT01058460 Not Applicable
45 DNA Methylation Biomarkers for Cervical Cancer Screening Unknown status NCT02605941
46 Quality of Life and Sexuality in Women With Gynaecological Cancer Unknown status NCT01589406
47 Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171 Unknown status NCT00898144
48 Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies Unknown status NCT02217215
49 Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study Completed NCT02323997
50 Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix Completed NCT00601601

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Genetic Tests for Cervix Uteri Carcinoma in Situ

Anatomical Context for Cervix Uteri Carcinoma in Situ

MalaCards organs/tissues related to Cervix Uteri Carcinoma in Situ:

41
Cervix, Testes, Breast, Liver, T Cells, Prostate, Bone

Publications for Cervix Uteri Carcinoma in Situ

Articles related to Cervix Uteri Carcinoma in Situ:

(show top 50) (show all 845)
# Title Authors Year
1
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. ( 29431861 )
2018
2
Risks of cervical intraepithelial neoplasia grade 3 or invasive cancers in ASCUS women with different management: a population-based cohort study. ( 29770625 )
2018
3
A prospective study on the predictive value of DNA methylation in cervical intraepithelial neoplasia prognosis. ( 29971561 )
2018
4
Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30-44 years: A case-control study in New South Wales, Australia. ( 29980028 )
2018
5
New biomarkers of human papillomavirus infection in acute cervical intraepithelial neoplasia. ( 29966832 )
2018
6
Distribution and role of high-risk human papillomavirus genotypes in women with cervical intraepithelial neoplasia: A retrospective analysis from Wenzhou, southeast China. ( 29851256 )
2018
7
Presence of koilocytosis in low-grade smears of high-risk HPV-positive women is a negative predictor for cervical intraepithelial neoplasia grade 3 or more. ( 29575519 )
2018
8
Clinical outcomes after conservative management of cervical intraepithelial neoplasia grade 2 (CIN2) in women ages 21-39 years. ( 29437696 )
2018
9
TOPical Imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): a study protocol for a randomized controlled trial. ( 29902979 )
2018
10
Diagnostic value of human papillomavirus (HPV) 16 and HPV18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV. ( 29353074 )
2018
11
Risk of preterm birth in women with cervical intraepithelial neoplasia grade one: a population-based cohort study. ( 29165793 )
2018
12
Medical Devices; Hematology and Pathology Devices; Classification of a Cervical Intraepithelial Neoplasia Test System. Final order. ( 29319946 )
2018
13
The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia. ( 29608253 )
2018
14
Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization. ( 29400020 )
2018
15
Clinical and Economic Value of p16INK4a for the Differential Diagnosis of Morphologic Cervical Intraepithelial Neoplasia 2. ( 29734247 )
2018
16
Factors affecting residual/recurrent cervical intraepithelial neoplasia after cervical conization with negative margins. ( 29704442 )
2018
17
Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up. ( 29369205 )
2018
18
Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation. ( 29319498 )
2018
19
Depth of Cervical Intraepithelial Neoplasia Grade 3 in Peruvian Women: Implications for Therapeutic Depth of Necrosis. ( 29271853 )
2018
20
Risk for Cervical Intraepithelial Neoplasia Grade 3 or Higher in Follow-Up of Women With a Negative Cervical Biopsy. ( 29543686 )
2018
21
Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. ( 29971397 )
2018
22
Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china. ( 29563617 )
2018
23
Characteristic findings of high-grade cervical intraepithelial neoplasia or more on magnifying endoscopy with narrow band imaging. ( 29446041 )
2018
24
Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. ( 29686397 )
2018
25
Prevalence of high-grade cervical intraepithelial neoplasia in women with persistent high-risk HPV genotypes and negative cytology. ( 29350424 )
2018
26
Differentiated cervical intraepithelial neoplasia-associated invasive cervical squamous cell carcinoma as a source of major cytopathological and surgical pathological discrepancy in Papanicolaou smear screening tests. ( 29575422 )
2018
27
Is self-sampling to test for high-risk papillomavirus an acceptable option among women who have been treated for high-grade cervical intraepithelial neoplasia? ( 29912903 )
2018
28
Analysis of differential gene expression caused by cervical intraepithelial neoplasia based on GEO database. ( 29805564 )
2018
29
Mass spectrometry and multivariate analysis to classify cervical intraepithelial neoplasia from blood plasma: an untargeted lipidomic study. ( 29500376 )
2018
30
Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection: A systematic review and meta-analysis of randomized clinical trials. ( 29794788 )
2018
31
Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. ( 29746299 )
2018
32
Early and late pregnancy outcomes in women treated with cold-coagulation versus LLETZ cervical treatment for cervical intraepithelial neoplasia; a retrospective cohort study. ( 29404740 )
2018
33
Using p16 immunohistochemistry to classify morphologic cervical intraepithelial neoplasia 2: correlation of ambiguous staining patterns with HPV subtypes and clinical outcome. ( 28705710 )
2017
34
Loop Electrosurgical Excision Procedure<i>vs</i>. Cold Knife Cone in Treatment of Cervical Intraepithelial Neoplasia: Review of 447 Cases. ( 29263039 )
2017
35
The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap. ( 28756395 )
2017
36
A prediction model for spontaneous regression of cervical intraepithelial neoplasia grade 2, based on simple clinical parameters. ( 27697590 )
2017
37
Authors' reply re: Assessing cervical intraepithelial neoplasia as an indicator disease for HIV in a low endemic setting: a population-based register study. ( 28921796 )
2017
38
A retrospective analysis on 1901 women with high grade cervical intraepithelial neoplasia by colposcopic biopsy. ( 28850822 )
2017
39
Bacterial Vaginosis and Cervical Intraepithelial Neoplasia: Is there an Association or is Co-Existence Incidental? ( 28610416 )
2017
40
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. ( 28833798 )
2017
41
Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells. ( 28521396 )
2017
42
Cryotherapy reduces progression of cervical intraepithelial neoplasia grade 1 in South African HIV-infected women: a randomized, controlled trial. ( 28902073 )
2017
43
LINE-1 hypermethylation in white blood cell DNA is associated with high-grade cervical intraepithelial neoplasia. ( 28854904 )
2017
44
Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia? ( 28817235 )
2017
45
Diagnostic and Treatment Reproducibility of Cervical Intraepithelial Neoplasia / Squamous Intraepithelial Lesion and Factors Affecting the Diagnosis. ( 28832077 )
2017
46
Effects of Long-Term Vitamin D Supplementation on Regression and Metabolic Status of Cervical Intraepithelial Neoplasia: a Randomized, Double-Blind, Placebo-Controlled Trial. ( 28050798 )
2017
47
Expression of p63, p53 and Ki-67 in Patients with Cervical Intraepithelial Neoplasia. ( 28044307 )
2017
48
Type-Dependent Association between Risk of Cervical Intraepithelial Neoplasia and Viral Load of Oncogenic Human Papillomavirus Types Other than Types 16 and 18. ( 28052328 )
2017
49
Increased Cervical HIV RNA Shedding Among HIV-Infected Women Randomized to Loop Electrosurgical Excision Procedure (LEEP) compared to Cryotherapy for Cervical Intraepithelial Neoplasia 2/3. ( 29272368 )
2017
50
Translation and cultural adaptation of the Functional Assessment of Chronic Illness Therapy - Cervical Dysplasia (FACIT-CD) to evaluate quality of life in women with cervical intraepithelial neoplasia. ( 28767912 )
2017

Variations for Cervix Uteri Carcinoma in Situ

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Pathways for Cervix Uteri Carcinoma in Situ

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.43 GP5 GP6 SERPIND1
2 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.32 FHIT TP53
3 positive regulation of cell cycle arrest GO:0071158 9.16 INSM1 TP53
4 replicative senescence GO:0090399 8.96 CDKN2A TP53
5 hemostasis GO:0007599 8.8 GP5 GP6 SERPIND1

Molecular functions related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 8.62 CDKN2A TP53

Sources for Cervix Uteri Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....